• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclo Therapeutics Inc (NQ: CYTH )

    0.7276 +0.0176 (+2.48%)
    Streaming Delayed Price Updated: 12:49 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cyclo Therapeutics Inc

    < Previous 1 2 3 4 Next >
    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
    Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
    Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
    From Pacira BioSciences
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
    From Cyclo Therapeutics
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
    From Rafael Holdings, Inc.; Cyclo Therapeutics
    Via GlobeNewswire
    Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
    Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
    Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
    Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.